Zacks Research Slightly Cuts Exelixis FY2027 EPS Estimate
Zacks Research lowered its fiscal 2027 earnings per share forecast for Exelixis to $3.56 from $3.59 while maintaining a Hold rating. The company recently reported quarterly EPS of $0.91, beating the $0.85 estimate, though revenue of $628.69 million rose 10.6% year over year but missed expectations. Exelixis shares opened at $59.86, near a 52-week high, as investors weighed zanzalintinib's potential against cabozantinib patent concerns.
Zacks Research trimmed its fiscal 2027 EPS view for Exelixis to $3.56 from $3.59, keeping a Hold rating. The broader analyst consensus also sits at Hold, with a $50.79 target. Exelixis recently posted quarterly EPS of $0.91, beating the $0.85 estimate, while revenue reached $628.69 million, up 10.6% year over year but below expectations.
Shares opened at $59.86, close to a 52-week high of $61.14. Investors are weighing zanzalintinib’s potential against cabozantinib patent-expiration and competition concerns. The stock’s 50-day and 200-day moving averages were $56.26 and $52.28, and its market cap was $14.83 billion.
Analyst estimate changes for Exelixis may influence investor sentiment, potentially affecting shareholders and the company’s ability to fund research. Patients and clinicians could be indirectly impacted if pipeline prospects such as zanzalintinib advance or if cabozantinib competition shifts. Broader biotech financing and drug development timelines may also be sensitive to such earnings signals, though clinical results and regulatory decisions remain the primary drivers. This is a reasoned perspective, not a prediction.